Rosario Domingo‐Jiménez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rosario Domingo‐Jiménez has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
A. Aranda
Centro Nacional de Alimentación, Instituto de Salud Carlos III, 28220 Majadahonda Madrid, Spain
1 shared publication- Alba Tristán-Noguero
Neurometabolic Unit and Synaptic Metabolism Lab, Neurology Department, Institut Pediàtric de Recerca and MetabERN Hospital Sant Joan de Déu Barcelona Spain
1 shared publication - Analia Bortolozzi
Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC)
1 shared publication - Angel Raya
Stem Cell Potency Group, Regenerative Medicine Program, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Spain
1 shared publication Antonella Consiglio
Department of Pathology and Experimental Therapeutics, Bellvitge University Hospital-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
1 shared publicationArianna Colini Baldeschi
Department of Pathology and Experimental Therapeutics, Bellvitge University Hospital-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
1 shared publication
Latest Publications
- Open Access
- 6 February 2023
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 15 (3) , e15847
iPSC‐based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation
Tyrosine hydroxylase deficiency (THD) is a rare genetic disorder leading to dopaminergic depletion and early‐onset Parkinsonism. Affected children present with either a severe form that does not respond to L‐Dopa treatment (THD‐B) or a milder L‐Dopa responsive form (THD‐A). We generated induced pluripotent stem cells (iPSCs) from THD patients that were differentiated into dopaminergic neurons (DAn) and compared with control‐DAn from healthy individuals and gene‐corrected isogenic controls. Consistent with patients, THD iPSC‐DAn displayed lower levels of DA metabolites and reduced TH expression, when compared to controls. Moreover, THD iPSC‐DAn showed abnormal morphology, including reduced total neurite length and neurite arborization defects, which were not evident in DAn differentiated from control‐iPSC. Treatment of THD‐iPSC‐DAn with L‐Dopa rescued the neuronal defects and disease phenotype only in THDA‐DAn. Interestingly, L‐Dopa treatment at the stage of neuronal precursors could prevent the alterations in THDB‐iPSC‐DAn, thus suggesting the existence of a critical developmental window in THD. Our iPSC‐based model recapitulates THD disease phenotypes and response to treatment, representing a promising tool for investigating pathogenic mechanisms, drug screening, and personalized management.
- 6 February 2023
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 15 (3) , e15847
Open AccessiPSC‐based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation
Tyrosine hydroxylase deficiency (THD) is a rare genetic disorder leading to dopaminergic depletion and early‐onset Parkinsonism. Affected children present with either a severe form that does not respond to L‐Dopa treatment (THD‐B) or a milder L‐Dopa responsive form (THD‐A). We generated induced pluripotent stem cells (iPSCs) from THD patients that were differentiated into dopaminergic neurons (DAn) and compared with control‐DAn from healthy individuals and gene‐corrected isogenic controls. Consistent with patients, THD iPSC‐DAn displayed lower levels of DA metabolites and reduced TH expression, when compared to controls. Moreover, THD iPSC‐DAn showed abnormal morphology, including reduced total neurite length and neurite arborization defects, which were not evident in DAn differentiated from control‐iPSC. Treatment of THD‐iPSC‐DAn with L‐Dopa rescued the neuronal defects and disease phenotype only in THDA‐DAn. Interestingly, L‐Dopa treatment at the stage of neuronal precursors could prevent the alterations in THDB‐iPSC‐DAn, thus suggesting the existence of a critical developmental window in THD. Our iPSC‐based model recapitulates THD disease phenotypes and response to treatment, representing a promising tool for investigating pathogenic mechanisms, drug screening, and personalized management.
- 1 April 1993
- Published by Elsevier in Analytica Chimica Acta
- Vol. 275 (1-2) , 317-321
Determination of dimetridazole residues in bovine tissue by liquid chromatography
- 1 April 1993
- Published by Elsevier in Analytica Chimica Acta
- Vol. 275 (1-2) , 317-321
Determination of dimetridazole residues in bovine tissue by liquid chromatography